Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

RAMIPRIL

All products: general benefit

Other products in the same Health Canada class (C09AA) — coverage varies; not interchangeable

  • Benazepril (Lotensin): general benefit, Not a benefit
  • Captopril (Noyada): general benefit, Limited Use 707, 723, Not a benefit
  • Cilazapril (Inhibace): general benefit, Not a benefit
  • Enalapril (Vasotec): general benefit, Not a benefit
  • Fosinopril (Monopril): general benefit, Not a benefit
  • Lisinopril (Prinivil): general benefit, Not a benefit

3 more in the class list below

Altace Cap · DIN 02221853 · 10mg ·

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Altace Cap · DIN 02221853 Manufacturer: Sanofi Aventis Pharma; listing date 1999-01-06 Health Canada: Marketed since 2021-01-11 · brand ALTACE · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 10 MG · company Bausch health, canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.1034 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43311 · Verify on the e-Formulary ↗ (DIN 02221853)

Source record
DIN 02221853: Altace Cap Raw flags: chronicUseMed=Y, sec3=Y Item: 240800206; group id 350; item number 0805; lccId None; manufacturer id SAV Source form: None; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.4872; ministry $0.1034 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02221853 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43311
Interchangeable products
AG-Ramipril Cap · DIN 02477599 · $0.1034 Apo-Ramipril Cap · DIN 02251582 · $0.1034 Auro-Ramipril Cap · DIN 02387417 · $0.1034 Co Ramipril Cap · DIN 02295512 · $0.1034 Jamp-Ramipril Cap · DIN 02331144 · $0.1034 Mar-Ramipril Cap · DIN 02420481 · $0.1034 Mint-Ramipril Cap · DIN 02421321 · $0.1034 NRA-Ramipril Cap · DIN 02486199 · $0.1034 PMSC-Ramipril Cap · DIN 02550237 · $0.1034 Pharma-Ramipril · DIN 02469081 · $0.1034 Ramipril Cap · DIN 02255332 · not recorded Ramipril Cap · DIN 02287943 · $0.1034 Ramipril Cap · DIN 02374862 · $0.1034 Ran-Ramipril Cap · DIN 02310546 · $0.1034 Teva-Ramipril Cap · DIN 02247947 · $0.1034
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02221853
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (24:08 Hypotensive Drugs (For Diuretics See 40:28)) and how they are covered

Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE, LABETALOL HCL, LOSARTAN POTASSIUM, LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE, MINOXIDIL, OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE, PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE & INDAPAMIDE, PINDOLOL & HYDROCHLOROTHIAZIDE, TELMISARTAN, TELMISARTAN & AMLODIPINE BESYLATE, TELMISARTAN & HYDROCHLOROTHIAZIDE, VALSARTAN & HYDROCHLOROTHIAZIDE Some products covered without a code (check the product listing): ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, CAPTOPRIL, CILAZAPRIL, CLONIDINE HCL, DOXAZOSIN MESYLATE, ENALAPRIL MALEATE, FELODIPINE, FOSINOPRIL SODIUM, HYDRALAZINE HCL, IRBESARTAN, IRBESARTAN & HYDROCHLOROTHIAZIDE, LISINOPRIL, LISINOPRIL & HYDROCHLOROTHIAZIDE, METHYLDOPA, NIFEDIPINE, PINDOLOL, PRAZOSIN HCL, QUINAPRIL, QUINAPRIL & HYDROCHLOROTHIAZIDE, RAMIPRIL & HYDROCHLOROTHIAZIDE, TERAZOSIN HCL, TRANDOLAPRIL, VALSARTAN, VERAPAMIL HCL 24:08 Hypotensive Drugs (For Diuretics See 40:28)

BENAZEPRIL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab

CAPTOPRIL

· 14 products · Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8) · strengths: 5mg/5mL, 25mg/5mL, 12.5mg, 25mg, 50mg, 100mg · Oral Sol, Tab

CILAZAPRIL

· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 1mg, 2.5mg, 5mg · Tab

ENALAPRIL MALEATE

· 52 products · Listed, not a benefit (1), General benefit (51) · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab

FOSINOPRIL SODIUM

· 12 products · Listed, not a benefit (2), General benefit (10) · strengths: 10mg, 20mg · Tab

LISINOPRIL

· 45 products · Listed, not a benefit (1), General benefit (44) · strengths: 5mg, 10mg, 20mg · Tab

PERINDOPRIL ERBUMINE

· 45 products · General benefit · strengths: 2mg, 4mg, 8mg · Tab

QUINAPRIL

· 12 products · Listed, not a benefit (4), General benefit (8) · strengths: 5mg, 10mg, 20mg, 40mg · Tab

TRANDOLAPRIL

· 26 products · Off-Formulary Interchangeable, not an ODB benefit (5), General benefit (21) · strengths: 0.5mg, 1mg, 2mg, 4mg · Cap

ATENOLOL & CHLORTHALIDONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50 & 25mg, 100 & 25mg · Tab

CANDESARTAN CILEXETIL

· 59 products · General benefit · strengths: 4mg, 8mg, 16mg, 32mg · Tab

CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE

· 21 products · General benefit · strengths: 16mg & 12.5mg, 32mg & 12.5mg, 32mg & 25mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:08 and 35 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: hypertension
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE ACEBUTOLOL HCL · Listed, not a benefit (3), General benefit (6) INDICATIONS AND CLINICAL USE APO-ACEBUTOLOL is indicated for the following:  Treatment of mild to moderate hypertension.  Long-term management of patients with angina pectoris due to ischemic heart disease. PM: https://pdf.hres.ca/dpd_pm/00047998.PDF; date October 24, 2018; DIN 02147602; fetched 2026-09-10 Product monograph AMLODIPINE · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (11), General benefit (44) 1 INDICATIONS NORVASC (amlodipine besylate tablets) is indicated for: • Hypertension NORVASC is indicated in the treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00071908.PDF; date AUG 02, 2023; DIN 00878928; fetched 2026-09-10 Product monograph AZILSARTAN MEDOXOMIL · Off-Formulary Interchangeable, not an ODB benefit 1 Part 1: Healthcare Professional Information Indications • EDARBI (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) indicated for the treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00082489.PDF; date 2025-10-24; DIN 02381389; fetched 2026-09-10 Product monograph BENAZEPRIL · Listed, not a benefit (3), General benefit (3) Indications BENAZEPRIL (benazepril hydrochloride tablets) is indicated for:  Treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00080887.PDF; date 2025-06-24; DIN 02273918; fetched 2026-09-10 Product monograph CANDESARTAN CILEXETIL · General benefit • Heart Failure o The treatment of NYHA Class II and III heart failure with ejection fraction ≤ 40% in addition to standard therapy, with or without an ACE inhibitor. 1.1 Pediatrics Pediatrics (6 to 17 years of age): • Hypertension ATACAND is indicated for the treatment of essential hypertension in children and adolescents 6 to 17 years of age (see 7.1.3 Pediatrics, 14 CLINICAL TRIALS). PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10 Product monograph • Hypertension PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10 Product monograph CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE · General benefit 1 INDICATIONS ATACAND PLUS (candesartan cilexetil/hydrochlorothiazide) is indicated for: • the treatment of essential hypertension in patients for whom combination therapy is appropriate. PM: https://pdf.hres.ca/dpd_pm/00076288.PDF; date JUN 18, 2001; DIN 02244021; fetched 2026-09-10 Product monograph CHLORTHALIDONE · Listed, not a benefit (1), General benefit (2) 1 INDICATIONS APO-CHLORTHALIDONE (chlorthalidone) is indicated for: • Treatment of hypertension. PM: https://pdf.hres.ca/dpd_pm/00069909.PDF; date MAR 14, 2023; DIN 00360279; fetched 2026-09-10 Product monograph CILAZAPRIL & HYDROCHLOROTHIAZIDE · General benefit 1 INDICATIONS INHIBACE PLUS (cilazapril and hydrochlorothiazide) is indicated for:  treatment of mild to moderate essential hypertension in patients for whom combination therapy with both cilazapril and hydrochlorothiazide is appropriate. PM: https://pdf.hres.ca/dpd_pm/00066994.PDF; date September 07, 1995; DIN 02181479; fetched 2026-09-10 Product monograph CLONIDINE HCL · Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2), General benefit (8) INDICATIONS AND CLINICAL USE TEVA-CLONIDINE (clonidine hydrochloride) is indicated for the treatment of hypertension. PM: https://pdf.hres.ca/dpd_pm/00024986.PDF; date April 25, 2014; DIN 02046121; fetched 2026-09-10 Product monograph ENALAPRIL MALEATE & HYDROCHLOROTHIAZIDE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS VASERETIC® (enalapril and hydrochlorothiazide) is indicated for:  Treatment of essential hypertension in patients for whom this combination therapy with enalapril and hydrochlorothiazide is appropriate. PM: https://pdf.hres.ca/dpd_pm/00068096.PDF; date November 4, 2022; DIN 00657298; fetched 2026-09-10 Product monograph and 20 more Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE ALTACE (ramipril) is indicated for:  Treatment of Essential Hypertension. It may be used alone or in association with thiazide diuretics or with the calcium channel blocker felodipine. The safety and efficacy of ALTACE in renovascular hypertension have not been established and therefore, its use in this condition is not recommended. ALTACE can also be tried as an initial agent in those patients in whom use of diuretics and/or beta blockers are contraindicated or in patients with medical conditions in which these drugs frequently cause serious adverse effects. The safety and efficacy of concurrent use of ALTACE with antihypertensive agents other than thiazide diuretics have not been established.  Treatment Following Acute Myocardial Infarction in clinically stable patients with signs of left ventricular dysfunction to improve survival and reduce hospitalizations for heart failure. Sufficient experience in the treatment of patients with severe (NYHA class IV) heart failure immediately after myocardial infarction is not yet available (see WARNINGS AND PRE… https://pdf.hres.ca/dpd_pm/00059606.PDF PM date: January 8, 2021 Source product: ALTACE; DIN 02221829; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.